Ranbaxy Laboratories
BSE: 500359 | NSE: RANBAXY | ISIN: INE015A01028 | Pharmaceuticals
Balance Sheet of Ranbaxy Laboratories |
------------------- in Rs. Cr. ------------------- |
|
Dec '04 |
Dec '05 |
Dec '06 |
Dec '07 |
Dec '08 |
 |
|
12 mths |
12 mths |
12 mths |
12 mths |
12 mths |
|
| Sources Of Funds |
|
|
|
|
| Total Share Capital |
185.89 |
186.22 |
186.34 |
186.54 |
210.19 |
| Equity Share Capital |
185.89 |
186.22 |
186.34 |
186.54 |
210.19 |
| Share Application Money |
2.83 |
0.28 |
0.88 |
1.18 |
175.66 |
| Preference Share Capital |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Reserves |
2,320.79 |
2,190.80 |
2,162.79 |
2,350.68 |
3,330.92 |
| Revaluation Reserves |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Networth |
2,509.51 |
2,377.30 |
2,350.01 |
2,538.40 |
3,716.77 |
| Secured Loans |
133.37 |
353.49 |
224.29 |
365.07 |
162.07 |
| Unsecured Loans |
2.49 |
676.31 |
2,954.31 |
3,137.96 |
3,563.30 |
| Total Debt |
135.86 |
1,029.80 |
3,178.60 |
3,503.03 |
3,725.37 |
| Total Liabilities |
2,645.37 |
3,407.10 |
5,528.61 |
6,041.43 |
7,442.14 |
|
Dec '04 |
Dec '05 |
Dec '06 |
Dec '07 |
Dec '08 |
|
|
12 mths |
12 mths |
12 mths |
12 mths |
12 mths |
|
| Application Of Funds |
|
|
|
|
| Gross Block |
1,402.79 |
1,799.32 |
2,133.57 |
2,261.48 |
2,386.75 |
| Less: Accum. Depreciation |
525.21 |
599.35 |
699.54 |
791.96 |
930.07 |
| Net Block |
877.58 |
1,199.97 |
1,434.03 |
1,469.52 |
1,456.68 |
| Capital Work in Progress |
264.16 |
432.84 |
301.88 |
327.42 |
428.77 |
| Investments |
679.07 |
762.78 |
2,679.95 |
3,237.55 |
3,618.03 |
| Inventories |
896.34 |
890.93 |
954.91 |
976.07 |
1,198.52 |
| Sundry Debtors |
784.69 |
806.62 |
1,013.75 |
882.91 |
1,024.54 |
| Cash and Bank Balance |
37.14 |
30.48 |
27.06 |
69.38 |
49.86 |
| Total Current Assets |
1,718.17 |
1,728.03 |
1,995.72 |
1,928.36 |
2,272.92 |
| Loans and Advances |
648.61 |
594.94 |
581.18 |
882.99 |
2,351.98 |
| Fixed Deposits |
0.13 |
86.11 |
44.09 |
111.07 |
1,885.08 |
| Total CA, Loans & Advances |
2,366.91 |
2,409.08 |
2,620.99 |
2,922.42 |
6,509.98 |
| Deffered Credit |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Current Liabilities |
1,011.53 |
983.57 |
985.57 |
1,177.35 |
3,840.11 |
| Provisions |
530.80 |
413.99 |
522.67 |
738.14 |
731.20 |
| Total CL & Provisions |
1,542.33 |
1,397.56 |
1,508.24 |
1,915.49 |
4,571.31 |
| Net Current Assets |
824.58 |
1,011.52 |
1,112.75 |
1,006.93 |
1,938.67 |
| Miscellaneous Expenses |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Total Assets |
2,645.39 |
3,407.11 |
5,528.61 |
6,041.42 |
7,442.15 |
|
| Contingent Liabilities |
307.95 |
202.40 |
159.40 |
201.00 |
252.85 |
| Book Value (Rs) |
134.85 |
63.82 |
63.03 |
68.01 |
84.24 |
|
|
|
|
| Source : Religare Technova |
| Explore Ranbaxy Labs connections |
|
